Aprepitant in adolescent patients for prevention of chemotherapy‐induced nausea and vomiting: A randomized, double‐blind, placebo‐controlled study of efficacy and tolerability

Gore, Lia; Chawla, Sant P.; Petrilli, A. S.; Hemenway, Molly; Schissel, Debra; Chua,; Ad, Carides; Taylor, Adekemi; DeVandry, Suzanne; Valentine, J L; Jk, Evans; Oxenius, Bettina

doi:10.1002/pbc.21811

Cited by 88 publications

(97 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pharmacokinetic disposition of aprepitant in adolescents has been shown to be similar to that observed in adults [24]. It is therefore reasonable to administer the adult dose to adolescents.…”

Section: What Doses Of Antiemetic Agents Are Known To Be Effective Inmentioning

confidence: 80%

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Dupuis

Boodhan

Holdsworth

et al. 2013

Pediatric Blood & Cancer

125

163

View full text Add to dashboard Cite

This guideline provides an approach to the prevention of acute antineoplastic‐induced nausea and vomiting (AINV) in children. It was developed by an international, inter‐professional panel using AGREE and CAN‐IMPLEMENT methods. Evidence‐based interventions that provide optimal AINV control in children receiving antineoplastic agents of high, moderate, low, and minimal emetogenicity are recommended. Recommendations are also made regarding selection of antiemetic agents for children who are unable to receive corticosteroids for AINV control, the role of aprepitant and optimal doses of antiemetic agents. Gaps in the evidence used to support the recommendations were identified. The contribution of this guideline to AINV control in children requires prospective evaluation. Pediatr Blood Cancer 2013; 60: 1073–1082. © 2013 Wiley Periodicals, Inc.

show abstract

Section: What Doses Of Antiemetic Agents Are Known To Be Effective Inmentioning

confidence: 80%

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Dupuis

Boodhan

Holdsworth

et al. 2013

Pediatric Blood & Cancer

125

163

View full text Add to dashboard Cite

show abstract

“…[11] Information regarding the use of aprepitant in younger children is growing and it is now approved in the United States for use in children 6 months of age and older. [30][31][32][33][34][35] Published experience with fosaprepitant in children is limited. [36] This recommendation places a high value on improved CINV control when control is likely to be difficult to achieve and on the negative consequences of uncontrolled CINV.…”

Section: Switching From Ondansetron To Granisetronmentioning

confidence: 99%

Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy‐Induced Nausea and Vomiting in Children With Cancer

Flank

Robinson

Holdsworth

et al. 2016

Pediatric Blood & Cancer

View full text Add to dashboard Cite

This clinical practice guideline provides an approach to the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) and the prevention of refractory CINV in children. It was developed by an international, interprofessional panel and is based on systematic literature reviews. Evidence-based interventions for the treatment of breakthrough and prophylaxis of refractory CINV are recommended. Gaps in the evidence used to support the recommendations made in this clinical practice guideline were identified. The contribution of these recommendations to breakthrough and refractory CINV control in children requires prospective evaluation. Pediatr

show abstract

“…It is important to broadly record side effects so that unexpected effects are not missed. It is only in recent trials, for example, that a link between the use of aprepitant and increases in neutropenia and febrile neutropenia have been reported although this has not been confirmed in other studies [13]. The measurement of quality of life gives an overall assessment of the impact on the antiemetic on the wellbeing of the patient.…”

Section: Design Issues In Clinical Trialsmentioning

confidence: 99%

Antiemetic research: future directions

Olver

Molassiotis

Aapro

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

Purpose and methods As a part of reviewing the Multinational Association of Supportive Care in Cancer (MASCC) antiemetic guidelines in Perugia in 2009, an expert group identified directions for future antiemetic research. Results and conclusions In future trials, the prediction of nausea and vomiting may combine algorithms based on observed prognostic factors relating to the patient and the anticancer therapy, the identification of the genes that code for receptors, and pharmacogenetic studies of the metabolism of drugs. Design issues for future trials include standardising the emetic stimulus across studies and finding the minimum tolerated effective dose and schedule of an antiemetic. Also control of delayed emesis is not independent of the control of acute emesis. The full range of side effects and the impact on global quality of life scores should be part of the routine assessment of an antiemetic. With current high rates of control of acute vomiting, future trials will need to consider new primary endpoints such as nausea, a complex symptom, where improvement is needed. Economic endpoints should be incorporated to ascertain the cost benefit of antiemetic prophylaxis, taking into account the impact of nausea on work capacity. New antiemetic drugs may be targeted at different receptors, such as opioid, cannabinoid and peptide YY receptors. New research is needed into determining the extent of corticosteroid use. The emetic potential of a range of newer cytotoxics particularly when used in combinations and different scheduling, such as prolonged oral dosing of cytotoxics and use of targeted therapies, are all areas in need of research. More antiemetic studies are needed in niche areas such as in patients receiving high dose chemotherapy, radiation therapy or combined modality therapy. Further evidence of the efficacy of newer antiemetic agents is required in children.

show abstract

Aprepitant in adolescent patients for prevention of chemotherapy‐induced nausea and vomiting: A randomized, double‐blind, placebo‐controlled study of efficacy and tolerability

Abstract: Aprepitant triple therapy was generally well tolerated; CR were greater with aprepitant, although not statistically significant. Pharmacokinetics suggest that the adult dosing regimen is appropriate for adolescents.

Cited by 88 publications

References 8 publications

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy‐Induced Nausea and Vomiting in Children With Cancer

Antiemetic research: future directions

Contact Info

Product

Resources

About